Thank you very much.
It's all about incentives, and when you have a 17% commission, it doesn't offer much of an incentive to give back. Certainly the Philippines is a good example. When it comes to remittances, the countries in order are China, India and the Philippines. That's where new Canadians are sending back money most to, and, yes, they've left but it's our gain. They're here. They're working here and offering an incentive to them so that they can send money back to those in need. I think that ought to be on the table, particularly in light of the fact that getting to 0.7% would be very expensive, again, as laudable a goal is that is.
I have about three minutes left. I wanted to ask Mr. Savoie something.
You talked about pharmacare, and on this committee we are talking about competitiveness. That's our focus. Traditionally if you asked an economist what competitiveness means and how we boost it, they would talk about tax cuts and they would talk about less regulation, less burdens, less red tape.
You talked about pharmacare in your brief. You mentioned it here today. Is it proper to understand pharmacare from a competitiveness perspective? Is it important from that angle? Talk about its value for Canadians from an economic perspective and what it can add to our society.